Deal brings together Novartis oncology capabilities with Myricx Bio’s next‑gen ADC platform
Sofinnova reports Myricx Bio to be acquired by Novartis
Deal brings together Novartis oncology capabilities with Myricx Bio’s next‑gen ADC platform
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.